Golden Dome: An aerospace engineer explains the proposed nationwide missile defense system
Trump is calling for the current budget to allocate US$25 billion to launch the initiative, which the government projected will cost $175 billion. He said Golden Dome will be fully operational before the end of his term in three years and will provide close to 100% protection.
The Conversation U.S. asked Iain Boyd, an aerospace engineer and director of the Center for National Security Initiatives at the University of Colorado Boulder, about the Golden Dome plan and the feasibility of Trump's claims. Boyd receives funding for research unrelated to Golden Dome from defense contractor Lockheed Martin.
Several countries, including China, Russia, North Korea and Iran, have been developing missiles over the past few years that challenge the United States' current missile defense systems.
These weapons include updated ballistic missiles and cruise missiles, and new hypersonic missiles. They have been specifically developed to counter America's highly advanced missile defense systems such as the Patriot and the National Advanced Surface-to-Air Missile System.
For example, the new hypersonic missiles are very high speed, operate in a region of the atmosphere where nothing else flies and are maneuverable. All of these aspects combined create a new challenge that requires a new, updated defensive approach.
Russia has fired hypersonic missiles against Ukraine in the ongoing conflict. China parades its new hypersonic missiles in Tiananmen Square.
So it's reasonable to think that, to ensure the protection of its homeland and to aid its allies, the U.S. may need a new missile defense capability.
Such a defense system requires a global array of geographically distributed sensors that cover all phases of all missile trajectories.
First, it is essential for the system to detect the missile threats as early as possible after launch, so some of the sensors must be located close to regions where adversaries may fire them, such as by China, Russia, North Korea and Iran. Then, it has to track the missiles along their trajectories as they travel hundreds or thousands of miles.
These requirements are met by deploying a variety of sensors on a number of different platforms on the ground, at sea, in the air and in space. Interceptors are placed in locations that protect vital U.S. assets and usually aim to engage threats during the middle portion of the trajectory between launch and the terminal dive.
The U.S. already has a broad array of sensors and interceptors in place around the world and in space primarily to protect the U.S. and its allies from ballistic missiles. The sensors would need to be expanded, including with more space-based sensors, to detect new missiles such as hypersonic missiles. The interceptors would need to be enhanced to enable them to address hypersonic weapons and other missiles and warheads that can maneuver.
Intercepting hypersonic missiles specifically involves several steps.
First, as explained above, a hostile missile must be detected and identified as a threat. Second, the threat must be tracked along all of its trajectory due to the ability of hypersonic missiles to maneuver. Third, an interceptor missile must be able to follow the threat and get close enough to it to disable or destroy it.
The main new challenge here is the ability to track the hypersonic missile continuously. This requires new types of sensors to detect hypersonic vehicles and new sensor platforms that are able to provide a complete picture of the hypersonic trajectory. As described, Golden Dome would use the sensors in a layered approach in which they are installed on a variety of platforms in multiple domains, including ground, sea, air and space.
These various platforms would need to have different types of sensors that are specifically designed to track hypersonic threats in different phases of their flight paths. These defensive systems will also be designed to address weapons fired from space. Much of the infrastructure will be multipurpose and able to defend against a variety of missile types.
In terms of time frame for deployment, it is important to note that Golden Dome will build from the long legacy of existing U.S. missile defense systems. Another important aspect of Golden Dome is that some of the new capabilities have been under active development for years. In some ways, Golden Dome represents the commitment to actually deploy systems for which considerable progress has already been made.
Israel's Iron Dome air defense system has been described as the most effective system of its kind anywhere in the world.
But even Iron Dome is not 100% effective, and it has also been overwhelmed on occasion by Hamas and others who fire very large numbers of inexpensive missiles and rockets at it. So it is unlikely that any missile defense system will ever provide 100% protection.
The more important goal here is to achieve deterrence, similar to the stalemate in the Cold War with the Soviet Union that was based on nuclear weapons. All of the new weapons that Golden Dome will defend against are very expensive. The U.S. is trying to change the calculus in an opponent's thinking to the point where they will consider it not worth shooting their precious high-value missiles at the U.S. when they know there is a high probability of them not reaching their targets.
That seems to me like a very aggressive timeline, but with multiple countries now operating hypersonic missiles, there is a real sense of urgency.
Existing missile defense systems on the ground, at sea and in the air can be expanded to include new, more capable sensors. Satellite systems are beginning to be put in place for the space layer. Sensors have been developed to track the new missile threats.
Putting all of this highly complex system together, however, is likely to take more than three years. At the same time, if the U.S. fully commits to Golden Dome, a significant amount of progress can be made in this time.
President Trump is requesting a total budget for all defense spending of about $1 trillion in 2026. So, $25 billion to launch Golden Dome would represent only 2.5% of the total requested defense budget.
Of course, that is still a lot of money, and a lot of other programs will need to be terminated to make it possible. But it is certainly financially achievable.
Similar to Iron Dome, Golden Dome will consist of sensors and interceptor missiles but will be deployed over a much wider geographical region and for defense against a broader variety of threats in comparison with Iron Dome.
A second-generation Golden Dome system in the future would likely use directed energy weapons such as high-energy lasers and high-power microwaves to destroy missiles. This approach would significantly increase the number of shots that defenders can take against ballistic, cruise and hypersonic missiles.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Iain Boyd, University of Colorado Boulder
Read more:
China's hypersonic missiles threaten US power in the Pacific – an aerospace engineer explains how the weapons work and the unique threats they pose
Israel's Iron Dome air defense system works well – here's how Hamas got around it
Is Russia looking to put nukes in space? Doing so would undermine global stability and ignite an anti-satellite arms race
Iain Boyd receives funding from the U.S. Department of Defense and Lockheed-Martin Corporation, a defense contractor that sells missile defense systems and could potentially benefit from the implementation of Golden Dome.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Walmart lifts outlook for sales, earnings despite tariffs
Big-box retailer Walmart hiked its outlook for sales and some earnings in results released Thursday, even as costs of goods imported to the United States rose after President Donald Trump's wide-ranging tariffs this year. Walmart is among major retailers reporting their financial results this week, with markets keeping close tabs on consumer patterns -- and signs of price increases -- as tariffs bite. The company topped analysts' quarterly sales estimates, with revenues for the three months ending July 31 at $177.4 billion, up 4.8 percent from the same period a year ago. But it missed earnings expectations with adjusted earnings-per-share (EPS) at 68 cents, lower than anticipated. US companies have been squeezed in recent months as tariffs raised the costs of importing certain foreign goods, although many mitigated the blow to consumers by bulking up on inventory before Trump introduced the new levies. The overall impact on US consumer prices appears limited for now but economists are closely monitoring the pass-through of costs to gauge if the inflation hit will be one-off or if there will be lingering effects. In its second quarter results released Thursday, Walmart raised its outlook, anticipating net sales to rise between 3.75 percent and 4.75 percent for the fiscal year, up from earlier expectations of 3.0 percent to 4.0 percent. It also raised its adjusted EPS outlook to a range of $2.52 to $2.62, up from $2.50 to $2.60 per share before. Walmart shares fell more than 3.4 percent in pre-market trading. Among segments, its global e-commerce sales rose 25 percent. Walmart noted that net sales growth internationally was boosted by segments including China, Mexico and Central America. E-commerce sales were up 26 percent for the United States, Walmart said in its report. Sales through store-fulfilled delivery channels grew nearly 50 percent, the company added. It noted strong sales growth as well in grocery, alongside health and wellness. Since returning to the presidency in January, Trump has imposed a 10-percent tariff on goods from most trading partners. Earlier this month, the 10-percent rate rose to varying levels for dozens of economies including the EU, Japan and South Korea, even as several had struck deals to avert even steeper levies. In May, Walmart warned of price increases due to higher tariffs, saying it might not be able to absorb all the additional pressures. In an earnings presentation released Thursday, Walmart maintained that it had "strong inventory management," but that there were also higher costs for imported goods. elm-bys/aha
Yahoo
11 minutes ago
- Yahoo
The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know
Key Points Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline. The company looks attractively valued following its underperformance over the past 12 months. 10 stocks we like better than Novo Nordisk › The past 12 months haven't been great for Novo Nordisk (NYSE: NVO). Its shares peaked last year and have been in a downward spiral due to unimpressive financial results, clinical setbacks, and mounting competition in its core areas of expertise. However, Novo Nordisk is looking to bounce back. Recent regulatory progress could be a positive step in that direction. Here's what investors need to know. Another important approval On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a household name, famous for helping people manage their weight, but this new indication could be a significant development. Here's why. MASH is a disease characterized by the accumulation of fat in the liver, leading to inflammation. According to some estimates, 22 million adults in the U.S. have MASH, although fewer, about 9 million, have clinically meaningful liver disease. That's not an insignificant number, and one might think that, given this large addressable market, there are many approved therapies for MASH. But that's not the case. Developing effective treatments has proven to be surprisingly challenging. Last year, the FDA approved the first therapy specifically for MASH. Now, Wegovy has become the first GLP-1 medicine to earn that indication. Although there are other treatments in development, Wegovy could carve out a decent market for itself in MASH, especially since it posted phase 3 results comparable to those of its only competitor on the market (for now): Rezdiffra, marketed by Madrigal Pharmaceuticals. Novo Nordisk is a significantly larger company with more funds, a larger marketing budget, and a larger sales team than its smaller peer. What will be the demand for Wegovy in MASH be? We can gather some clues from Rezdiffra's launch, which is going extremely well. About a year after it hit the market, Rezdiffra generated $212.8 million in revenue in the second quarter -- that's impressive and points to a massive demand for the medicine. Yet, Madrigal has barely scratched the surface of the addressable market. As of June 30, it had treated just over 23,000 patients. Wegovy's launch in MASH should be even smoother since it isn't starting from scratch -- it's already been on the market for several years. In my view, this new indication could add over $1 billion in sales to Wegovy's total within the next few years, especially because it's also being considered for approval for MASH in Japan and the European Union. It's also worth pointing out another development that helped jolt Novo Nordisk's stock price. The company is partnering with GoodRx to offer Ozempic at a reduced cost for patients who pay out of pocket. This move should help it deal with some companies that sell compounded versions of Ozempic for less. Is Novo Nordisk's stock a buy? Wegovy could earn yet another important label expansion by next year, although in a different version. Earlier this year, Novo Nordisk requested approval for an oral formulation of the medicine for weight loss. That could also move the needle for the pharmaceutical giant. An oral version would be faster and cheaper to produce, easier to transport, and thus more cost-effective to manufacture at scale. The previous shortages Wegovy dealt with would be far less likely to occur with an oral formulation. Notably, it would mark yet another breakthrough for Novo Nordisk. There is currently no oral GLP-1 medication approved for weight loss -- the drugmaker's own Rybelsus, an oral GLP-1 product, is indicated only for diabetes. Meanwhile, Novo Nordisk's financial results remain strong. In the first half of the year, net sales grew by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit of 55.5 billion DKK ($8.7 billion) rose 22% compared to the year-ago period. Furthermore, Novo Nordisk has an attractive pipeline. CagriSema, a next-generation GLP-1 therapy whose phase 3 results were strong (if not as strong as the market had hoped), appears poised to become a blockbuster. Some analysts predict that it will generate $15.2 billion in revenue by 2030. Elsewhere, Novo Nordisk's amycretin, another investigational weight loss therapy, recently started phase 3 studies in both oral and subcutaneous formulations. Despite recent clinical setbacks, Novo Nordisk's pipeline should earn some significant wins in the next few years, particularly since the company has been strengthening it through licensing deals. Lastly, Novo Nordisk stock looks reasonably valued. The company is trading at 13.5 times forward earnings, compared to an average price-to-earnings ratio of 16.5 for the healthcare industry. At current levels, the stock could deliver superior returns to investors who initiate positions today. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,624!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,117!* Now, it's worth noting Stock Advisor's total average return is 1,052% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Economic impact of US tariffs will be key for US rating, says S&P analyst
By Davide Barbuscia NEW YORK (Reuters) -S&P Global Ratings' decision to affirm its U.S. credit rating reflected the impact of tariff revenues, but questions remain on the economic outcome of U.S. trade policies that could influence the country's rating in the next few years, the primary analyst on the U.S. said. S&P on Monday affirmed its "AA+" credit rating on the U.S., saying the revenue from President Donald Trump's tariffs has the potential to offset the fiscal hit from his massive tax-cut and spending bill. S&P, which became the first ratings agency to cut the pristine U.S. government rating in 2011, said the outlook on the U.S. rating remains stable. "Outcomes are what's really going to weigh and inform the rating," Lisa Schineller, primary U.S. analyst at S&P Global Ratings, said in an interview. "The outcomes of how you execute the budgetary legislation, how the tariff revenue comes, their combined impact on growth and investment that leads to either better or worse or similar fiscal out-turns, that's our focus," she said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data